SAN FRANCISCO and NEW ORLEANS, Nov. 15, 2016 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC ), a leading digital health care solutions company focused on the advancement of cardiac care, announced that study results presented today during the American Heart Association (AHA) Scientific Sessions suggest that extended continuous cardiac monitoring using its Zio® system is more useful for arrhythmia detection than Holter monitoring in patients with adult congenital heart disease (ACHD).
The study, “The Days of the Holter Monitor Are Numbered: Extended Rhythm Monitoring Detects More Clinically Significant Arrhythmias in Adults with Congenital Heart Disease,” analyzed 387 ACHD patients’ results from extended continuous cardiac monitoring with the Zio system from June 2013 to May 2016. Fifty-one percent of these patients were found to have a significant arrhythmia, fewer than half of which were noted during the first 48 hours of monitoring.
Traditional Holter monitors are often used to assess arrhythmia burden in ACHD patients. However, only 24 to 48 hours of data can be collected at a time. Extended continuous monitoring utilizing the Zio system by iRhythm can record up to two weeks of continuous cardiac rhythm data, allowing it to detect significant arrhythmias beyond the Holter Monitor’s 48-hour monitoring period.
“Arrhythmias are a leading cause of death in adults with congenital heart disease, and extended continuous cardiac monitoring is essential to their arrhythmia management and risk assessment,” said lead researcher Scott Ceresnak, M.D., Assistant Professor, Pediatric Cardiology, Lucile Salter Packard Children’s Hospital. “The Zio system allows for monitoring beyond the traditional 48-hour period, helping to identify arrhythmias in ACHD patients which otherwise may not be detected.”
Zio by iRhythm is the first long-term continuous monitoring system that is supported by extensive clinical data with peer-reviewed publications, and enables diagnosis earlier in the clinical pathway to improve patient outcomes.
“The additional data captured by extended continuous cardiac monitoring allows for a definitive diagnosis in a single test to accelerate care,” said Judy Lenane, RN, MHA, executive vice president of operations and chief clinical officer of iRhythm Technologies, Inc. “This research adds to the growing body of scientific evidence showing the advantages of extended continuous monitoring in detecting arrhythmias over time. Utilizing iRhythm’s unique data warehouse and cloud-based analytics platform, the reliable and clinically actionable information provides a path forward.”
About iRhythm Technologies, Inc. iRhythm is a commercial-stage digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients. The company’s platform, the Zio Service, has been provided to over 500,000 patients, accumulating more than 125 million hours of curated heartbeat data within iRhythm’s data repository.
Investor Relations Contact Lynn Pieper Lewis or Leigh Salvo (415) 937-5404 investors@irhythmtech.com Media Contact Aaron Murphy media@irhythmtech.com 415-229-3331
